Medtronic makes concessions to European regulator in bid to close Covidien deal

Medtronic ($MDT) submitted unspecified concessions to the European Commission in a bid to close its $43 billion bid for Covidien ($COV) by early 2015. Overcoming antitrust concerns in various regions is one of the last impediments to the transaction. Last month, Covidien sold its clinical-stage drug-coated balloon to please antitrust authorities in the U.S. The European Commission will decide whether to approve the transaction by Nov. 28. News

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.